| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Net revenue | 260 | 518 | ||
| Cost of revenues | 121 | 168 | ||
| Cost of revenues amortization of acquired intangibles | 0 | 0 | ||
| Gross profit | 139 | 350 | ||
| Research and development | 3,878 | 3,281 | ||
| Sales and marketing | 1,386 | 1,460 | ||
| General and administrative | 2,545 | 2,647 | ||
| Change in fair value of contingent consideration | 3,378 | 2,804 | ||
| Impairment loss on held for sale assets | 0 | 0 | ||
| Total operating expenses | 11,187 | 10,192 | ||
| Loss from operations | -11,048 | -9,842 | ||
| Interest expense | -29 | -25 | ||
| Other income, net | 223 | 125 | ||
| Total other income, net | 194 | 100 | ||
| Loss before income taxes | -10,854 | -9,742 | ||
| Income taxes | - | 0 | ||
| Net loss | -10,854 | -9,742 | ||
| Net loss attributable to common stockholders per share - basic | -0.34 | -0.3 | ||
| Net loss attributable to common stockholders per share - diluted | -0.34 | -0.3 | ||
| Weighted average shares outstanding - basic | 32,033,000 | 32,023,000 | ||
| Weighted average shares outstanding - diluted | 32,033,000 | 32,023,000 | ||
Insight Molecular Diagnostics Inc. (IMDX)
Insight Molecular Diagnostics Inc. (IMDX)